Última actualización :
08/05/2024
Fármacos contra el cáncer   Paclitaxel  
Inyectables
Estabilidad en solucion Estabilidad en mezcla Factores que influyen sobre la estabilidad Compatibilidades Método de inyección Bibliografía Pdf
   Estructura química  

Nombre comercial   Nombre comercial     

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Aclipak Malasia
Acoexcel México
Actaxel Suecia
Acupaxil Marruecos
Anzatax Arabia Saudita, Emiratos Árabes Unidos, Turquía
Aritaxel Alemania
Cantaxel India
Clitaxel Argentina
Dalys Argentina
Difren Argentina
Ebetaxel Arabia Saudita, Austria
Genexol Hungría
Onxol Estados Unidos de América
Paclinova Argentina
Paclired Brasil
Paclitaxin Países Bajos
Parexel Ecuador
Paxene Dinamarca, España, Finlandia, Grecia
Poltaxel Polonia
Ribotax Alemania
Taxol Alemania, Australia, Austria, Bélgica, Colombia, Croacia, Dinamarca, Egipto, Emiratos Árabes Unidos, España, Estados Unidos de América, Finlandia, Francia, Gran Bretaña, Grecia, Hungría, Irlanda, Italia, Japón, Luxemburgo, Malasia, Marruecos, Marruecos, Nueva Zelanda, Polonia, Portugal, Suecia, Suiza, Turquía, Venezuela
Taxomedac Alemania
Vitax Turquía
Bibliografía   Inyectables   Bibliografía : Paclitaxel  
Tipo Publicación
38 Periódico Allwood MC, Martin HJ.
The extraction of diethylhexylphtalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection.
Int J Pharm 1996 ; 127: 65-71.
47 Periódico Burm JP, Jhee SS, Chin A, Moon YSK.
Stability of paclitaxel with ondansetron or ranitidine hydrochloride during simulated Y site administration.
Am J Hosp Pharm 1994 ; 51: 1201-1204.
57 Periódico Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
85 Periódico Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
140 Periódico Pearson SD, Trissel LA.
Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components.
Am J Hosp Pharm 1993 ; 50: 1405-1409.
151 Periódico Burm JP, Choi JS, Jhee SS, Chin A, Ulrich RW, Gill MA.
Stability of paclitaxel and fluconazole during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 2704-2706.
157 Periódico Xu QA, Trissel LA, Martinez JF.
Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32°C.
Am J Hosp Pharm 1994 ; 51: 3058-3060.
158 Periódico Trissel LA, Xu QA, Kwan J, Martinez JF.
Compatibility of paclitaxel injection vehicle with intravenous administration and extension sets.
Am J Hosp Pharm 1994 ; 51: 2804-2810.
173 Periódico Williams DA, Naik A.
Precipitation of paclitaxel from continuous infusion fluids.
J Infus Chemother 1994 ; 4: 140-142.
182 Periódico Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
248 Periódico Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Periódico Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
250 Periódico Mazzo DJ, Nguyen-Huu JJ, Pagniez S, Denis P.
Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials.
Am J Health-Syst Pharm 1997 ; 54: 566-569.
251 Periódico Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Periódico Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Periódico Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
412 Periódico Waugh WN, Trissel LA, Stella VJ.
Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers.
Am J Hosp Pharm 1991 ; 48: 1520-1524.
669 Periódico Chin A, Ramakrishnan RR, Yoshimura NN, Jeong EWS, Nii LJ, DiMeglio LS.
Paclitaxel stability and compatibility in polyolefin containers.
Ann Pharmacotherapy 1994 ; 28: 35-36.
872 Periódico Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F.
Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions.
Ann Pharmacotherapy 1997 ; 31: 1465-1470.
921 Periódico Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026 Periódico Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1286 Periódico Trissel LA, Xu QA, Gilbert DL.
Compatibility and stability of paclitaxel combined with doxorubicin hydrochloride in infusion solutions.
Ann Pharmacotherapy 1998 ; 32: 1013-1016.
1410 Periódico Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Periódico Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Periódico Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496 Periódico Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1520 Laboratorio Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1522 Laboratorio Macoflex N®
Maco Pharma 2001
1625 Periódico Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Periódico Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1741 Periódico Pfeifer RW, Hale KN, Cronquist SE, Daniels M.
Precipitation of paclitaxel during infusion by pump.
Am J Hosp Pharm 1993 ; 50: 2518-2521.
1865 Periódico Sautou-Miranda V, Brigas F, Vanheerswinghels S, Chopineau J.
Compatibility of paclitaxel in 5% glucose solution with ECOFLAC® low-density polyethylene containers - Stability under different storage conditions.
Int J Pharm 1999 ; 178: 77-82.
1925 Periódico Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1940 Periódico Xu QA, Trissel LA.
Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 1596-1598.
1953 Periódico Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1956 Laboratorio Paclitaxel - Summary of Product Characteristics
Hospira UK Limited 2015
1961 Periódico Kim SC, Yoon HJ, Lee JW, Yu J, Park ES, Chi SC.
Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles.
Int J Pharm 2005 ; 293: 303-310.
1982 Periódico Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2014 Periódico Pourroy B, Botta C, Solas C, Lacarelle B, Braguer D.
Seventy-two-hour stability of Taxol® in 5% dextrose or 0.9% sodium chloride in Viaflo®, Freeflex®, Ecoflac® and Macoflex N® non PVC bags.
J Clin Pharm Ther 2005 ; 30: 455-458.
2172 Periódico Donyai P, Sewell GJ.
Physical and chemical stability of paclitaxel infusions in different container types.
J Oncol Pharm Practice 2006 ; 12, 4: 211-222.
2174 Periódico Kattige A.
Long-term physical and chemical stability of a generic paclitaxel infusion under simulated storage and clinical-use conditions.
EJHP Science 2006 ; 12, 6: 129-134.
2262 Periódico Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2344 Laboratorio Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
Ebewe Pharma 2009
3093 Periódico Tian J, Stella VJ.
Degradation of paclitaxel and related compounds in aqueous solutions III: Degradation under acidic pH conditions and overall kinetics
J Pharm Sci 2010 ; 99, 3 : 1288-1298.
3277 Periódico Yang Z, Cameron S, Paul H.
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration.
Int J Pharm Compound 2012 ; 16, 1 : 82-85.
3578 Laboratorio Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011

  Mentions Légales